Pharmacological trials: primary and secondary prevention of coronary heart disease

Keyphrases

• Pharmacological Assays 100%
• Primary Prevention 100%
• Coronary Heart Disease Prevention 100%
• Secondary Prevention 100%
• Lipids 50%
• Adverse Effects 50%
• Platelets 50%
• Lipoproteins 33%
• Aspirin 33%
• Non-fatal 33%
• Clofibrate 33%
• Nicotinic Acid 33%
• Cigarette Smoking 16%
• Incongruity 16%
• Long-term Mortality 16%
• Risk-benefit Ratio 16%
• Plasma Lipids 16%
• Cholesterol 16%
• Middle-aged 16%
• All-cause Mortality 16%
• Resin 16%
• Combined Therapy 16%
• Dipyridamole 16%
• Lipoprotein Metabolism 16%
• Conjugated Equine Estrogens 16%
• Lipid-lowering Drugs 16%
• Death Events 16%
• Stroke Event 16%
• CHD Risk 16%
• Mortality from All Causes 16%
• No-place 16%
• Cholestyramine 16%
• Atherogenic Lipoproteins 16%
• Early Termination 16%
• Sedentary Living 16%
• Secondary Prevention Trials 16%
• Strategic Thrusts 16%
• Lipid Reduction 16%
• Mass Problems 16%
• Epidemic Control 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipoprotein 100%
• Ischemic Heart Disease 100%
• Acetylsalicylic Acid 66%
• Nicotinic Acid 66%
• Clofibrate 66%
• Diseases 66%
• Conjugated Estrogen 33%
• Cigarette Smoking 33%
• Prematurity 33%
• All Cause Mortality 33%
• Antilipemic Agent 33%
• Cerebrovascular Accident 33%
• Colestyramine 33%
• Dextrothyroxine 33%
• Sulfinpyrazone 33%
• Ethinylestradiol 33%
• Cytidine Diphosphate 33%
• Dipyridamole 33%